The Impact of Sinopharm COVID-19 Vaccination on Male Fertility
1 other identifier
observational
100
1 country
1
Brief Summary
The investigators shall study the effect of Sinopharm vaccination on semen parameters and serum testosterone
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jul 2021
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 28, 2021
CompletedFirst Posted
Study publicly available on registry
July 1, 2021
CompletedStudy Start
First participant enrolled
July 3, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 30, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
August 30, 2022
CompletedJuly 7, 2021
July 1, 2021
12 months
June 28, 2021
July 3, 2021
Conditions
Outcome Measures
Primary Outcomes (4)
Sperm density count/ml
As measured from semen samples
up to 6 months
Total sperm count per ejaculate
As measured from semen samples
up to 6 months
Percentage of motile sperm
As measured from semen samples
up to 6 months
Percentage of abnormal sperm forms
As measured from semen samples
up to 6 months
Secondary Outcomes (1)
Morning serum testosterone
up to 6 months
Study Arms (1)
Sinopharm vaccine group
Participants scheduled to receive the Sinopharm vaccine will be evaluated on its effect on semen parameters for up to 6 months post vaccination.
Interventions
Semen analysis according to WHO laboratory manual for the examination and processing of human semen, Fifth edition
Eligibility Criteria
Men of reproductive age scheduled for COVID-19 Sinopharm Vaccine
You may qualify if:
- Receiving Sinopharm COVID-19 vaccines Male age 18-50 years old
You may not qualify if:
- Adults unable to consent
- Men who have been receiving Testosterone replacement therapy or anabolic steroids within the last year
- Men with a history of male infertility
- Men with a genetic or other medical condition known to be associated with decreased semen parameters Positive COVID-19 PCR test within the 3 months
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Cairo Universitylead
Study Sites (1)
Faculty of Medicine, Cairo University
Cairo, 11562, Egypt
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Mohamed Tarek H Anis, M.D.
Cairo University
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Andrology
Study Record Dates
First Submitted
June 28, 2021
First Posted
July 1, 2021
Study Start
July 3, 2021
Primary Completion
June 30, 2022
Study Completion
August 30, 2022
Last Updated
July 7, 2021
Record last verified: 2021-07